DLBCL Interim Response Evaluation for Customised Therapy

UnknownOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

September 17, 2020

Primary Completion Date

September 1, 2025

Study Completion Date

September 1, 2025

Conditions
High-grade B-cell Lymphoma
Interventions
OTHER

Not Applicable as this is a translational, sample collection study.

"Patients will take their normal standard of care treatment for their lymphoma, as per agreed with the patient's doctor.~Blood samples will be collected at Baseline, during the first 3 cycles of Treatment, at End of Treatment, at 6- and 12-months after End of Treatment and at relapse/progression if applicable.~Surplus Tissue biopsy will be collected at Baseline and at relapse/progression if applicable. In rare cases research-specific tissue biopsy may be collected if appropriate."

Trial Locations (1)

CB2 0QQ

RECRUITING

Cambridge University Hospitals NHS Foundation Trust, Cambridge

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Cancer Research UK Cambridge Institute

OTHER

lead

Cambridge University Hospitals NHS Foundation Trust

OTHER